Profile data is unavailable for this security.
About the company
AlzeCure Pharma AB is a Sweden-based pharmaceutical research and development company with a primary focus on Alzheimer’s disease and other brain disease indications. The Company develops five drug candidates within its two main research programs, NeuroRestore and Alzstatin. The drug candidates in NeuroRestore stimulate a central signaling pathway in the brain that is essential for the functioning of nerve cells and has a strong genetic link to cognitive disorders, such as Alzheimer's disease. The main drug candidate, ACD855, is an already approved veterinary medicine available for the treatment of central nervous system (CNS) indications in animals and has undergone preclinical trials for human indications of impaired cognitive disorders. Alzstatin focuses on reducing the production of toxic amyloid beta (Aβ) protein in the brain. Aβ plays a central role in the pathology of Alzheimer’s disease and starts to accumulate in the brain many years before the first symptoms are recognized.
- Revenue in SEK (TTM)0.00
- Net income in SEK-39.20m
- Incorporated2016
- Employees11.00
- LocationAlzeCure Pharma ABHalsovagen 7HUDDINGE 141 57SwedenSWE
- Websitehttps://www.alzecurepharma.se/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SoftOx Solutions AS | 12.76m | -2.82m | 136.35m | 5.00 | -- | 1.34 | 180.23 | 10.68 | -0.001 | -0.001 | 0.0065 | 0.0445 | 0.123 | -- | 30.13 | 2,717,798.00 | -2.72 | -50.91 | -3.22 | -67.07 | -- | -- | -22.07 | -644.92 | 1.16 | -3.92 | 0.1212 | -- | 13.38 | 14.06 | -8.86 | -- | -- | -- |
| NextCell Pharma AB | 10.94m | -35.14m | 159.96m | 24.00 | -- | 2.41 | -- | 14.63 | -0.4414 | -0.4414 | 0.133 | 0.596 | 0.1384 | 51.23 | 4.68 | -- | -44.48 | -34.95 | -49.25 | -37.53 | -155.37 | -266.34 | -321.31 | -427.08 | 9.92 | -- | -- | -- | 2.56 | 25.13 | 16.25 | -- | 36.88 | -- |
| ViroGates A/S | 7.15m | -17.56m | 161.89m | 7.00 | -- | 33.56 | -- | 22.65 | -1.63 | -1.63 | 0.6609 | 0.3665 | 0.3568 | 0.9777 | 4.41 | 504,300.00 | -87.63 | -54.92 | -131.36 | -63.15 | 47.33 | 72.98 | -245.63 | -215.48 | 1.58 | -16.13 | 0.6277 | -- | -12.27 | 6.45 | -18.59 | -- | -- | -- |
| SenzaGen AB | 57.88m | -16.18m | 164.63m | 37.00 | -- | 2.22 | -- | 2.84 | -0.5483 | -0.5483 | 1.96 | 2.52 | 0.5577 | 5.47 | 6.63 | 1,702,294.00 | -15.59 | -20.91 | -18.89 | -25.17 | 65.09 | 67.10 | -27.95 | -71.43 | 2.73 | -- | 0.0707 | -- | 15.69 | 84.16 | 19.22 | -- | -1.18 | -- |
| Oncoinvent ASA | 5.08m | -101.06m | 177.86m | 7.00 | -- | 0.3849 | -- | 35.03 | -176.33 | -176.33 | 8.86 | 109.85 | 0.0354 | -- | 0.4134 | 360,333.30 | -70.49 | -68.76 | -88.81 | -82.93 | -- | -- | -1,990.44 | -40,397.77 | -- | -- | 0.00 | -- | 139.55 | -37.51 | 26.85 | -- | -- | -- |
| Klaria Pharma Holding AB (publ) | 11.23m | -58.70m | 202.68m | 4.00 | -- | 44.60 | -- | 18.04 | -0.4069 | -0.3093 | 0.0699 | 0.0185 | 0.201 | -- | 5.34 | 2,808,250.00 | -105.02 | -48.20 | -649.38 | -74.06 | -- | -- | -522.58 | -1,522.52 | -- | -2.47 | 0.1195 | -- | -73.41 | -11.85 | -33.44 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -16.44m | 203.76m | 2.00 | -- | 4.44 | -- | -- | -0.2729 | -0.2729 | 0.00 | 0.671 | 0.00 | -- | -- | 0.00 | -43.00 | -67.58 | -46.15 | -73.43 | -- | -- | -- | -- | -- | -- | 0.0619 | -- | -- | -- | 53.32 | -- | -- | -- |
| Xbrane Biopharma AB | 209.08m | -72.86m | 206.47m | 26.00 | -- | 0.3517 | -- | 0.9875 | -5.16 | 8.99 | 14.57 | 28.49 | 0.2713 | 0.2899 | 5.00 | 3,216,539.00 | -9.46 | -37.48 | -15.30 | -65.13 | 71.25 | -- | -34.85 | -233.69 | 1.71 | -1.49 | 0.00 | -- | -16.76 | -- | 17.70 | -- | 113.17 | -- |
| Dextech Medical AB | 0.00 | -4.96m | 210.74m | 1.00 | -- | 8.81 | -- | -- | -0.2684 | -0.2684 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -18.58 | -19.36 | -18.94 | -19.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.96 | -- | 40.14 | -- |
| AlzeCure Pharma AB | 0.00 | -39.20m | 218.34m | 11.00 | -- | 4.31 | -- | -- | -0.4047 | -0.4047 | 0.00 | 0.4409 | 0.00 | -- | -- | 0.00 | -71.83 | -73.70 | -88.08 | -83.65 | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | 5.20 | -- | -38.94 | -- |
| Promimic AB | 45.57m | -12.13m | 223.87m | 18.00 | -- | 3.67 | -- | 4.91 | -0.6388 | -0.6388 | 2.40 | 3.23 | 0.603 | -3.56 | 3.62 | 2,398,421.00 | -16.05 | -20.50 | -18.57 | -24.44 | 105.07 | 104.49 | -26.62 | -59.75 | 3.52 | -- | 0.00 | -- | 18.63 | 50.25 | -36.09 | -- | -- | -- |
| Sprint Bioscience AB | 49.53m | -25.65m | 228.97m | 29.00 | -- | 37.76 | -- | 4.62 | -0.2986 | -0.2986 | 0.5832 | 0.0575 | 1.47 | -- | 6.02 | 1,303,316.00 | -76.04 | -60.40 | -262.43 | -100.72 | 61.94 | 57.87 | -51.79 | -87.25 | -- | -36.01 | 0.00 | -- | 30.02 | 14.37 | -4,072.83 | -- | 69.39 | -- |
| Circio Holding ASA | 0.00 | -8.64m | 236.44m | 9.00 | 9.64 | -- | -- | -- | 0.1348 | 0.1348 | 0.00 | -0.0836 | 0.00 | -- | -- | 0.00 | -93.87 | -47.84 | -- | -58.78 | -- | -- | -- | -6,460.26 | -- | -- | -- | -- | -100.00 | -- | 150.93 | -- | 7.12 | -- |
| Xintela AB | 2.96m | -42.28m | 240.29m | 13.00 | -- | -- | -- | 81.26 | -0.0665 | -0.0665 | 0.0046 | -0.0396 | 0.3486 | -- | 6.47 | 227,461.50 | -498.42 | -194.17 | -- | -651.77 | 100.00 | -- | -1,429.86 | -6,272.93 | -- | -16.40 | -- | -- | 5,303.85 | 156.45 | 27.54 | -- | -- | -- |
| Bio-Works Technologies AB | 41.41m | -29.78m | 277.98m | 29.00 | -- | 7.57 | -- | 6.71 | -0.50 | -0.50 | 0.5878 | 0.3738 | 0.6931 | 0.9866 | 6.45 | 1,380,200.00 | -49.84 | -50.49 | -67.92 | -61.39 | 72.68 | 70.42 | -71.91 | -140.95 | 1.65 | -- | 0.00 | -- | -41.99 | 35.51 | 34.25 | -- | -48.46 | -- |
| Intervacc AB | 21.09m | -63.31m | 295.83m | 15.00 | -- | 0.9529 | -- | 14.03 | -0.3776 | -0.3776 | 0.09 | 0.911 | 0.079 | 0.8382 | 3.54 | 1,406,067.00 | -23.70 | -20.93 | -25.78 | -22.44 | 29.03 | -7.76 | -300.17 | -753.03 | 9.53 | -- | 0.0003 | -- | 47.06 | -0.5868 | 26.58 | -- | -52.41 | -- |
